Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carla Estany is active.

Publication


Featured researches published by Carla Estany.


AIDS | 2010

High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study

Anna Bonjoch; Marta Figueras; Carla Estany; Núria Pérez-Álvarez; Joaquim Rosales; Luis Del Rio; Silvana Di Gregorio; Jordi Puig; Guadalupe Gómez; Bonaventura Clotet; Eugenia Negredo

Background:Low bone mineral density (BMD) is an emerging metabolic condition in HIV-infected patients; however, data on progression of this disease are scarce. Methods:We studied 671 patients with at least one dual-energy X-ray absorptiometry scan (391 of them ≥2 scans) to determine the prevalence and progression of BMD and establish related factors. Linear regression and logistic polytomic regression were used for the cross-sectional study and mixed effects and generalized estimating equations were used for the longitudinal study. Results:Osteopenia and osteoporosis were diagnosed in 47.5 and 23%, respectively. Progression to bone demineralization was observed in 28% of the patients over a median of 2.5 years (12.5% progressed to osteopenia and 15.6% to osteoporosis). In the 105 patients with at least 5 years of follow-up, progression was 47% (18% to osteopenia; 29% to osteoporosis). Factors associated with bone loss and progression were age [odds ratio (OR) 1.07; 95% confidence interval (CI) 1.05–1.08; P < 0.0001], male sex (OR 2.23; 95% CI 1.77–2.8; P < 0.0001), low body mass index (OR 1.14; 95% CI 1.11–1.17; P < 0.0001), time on protease inhibitor (OR 1.18; 95% CI 1.12–1.24; P < 0.0001), time on tenofovir (OR 1.08; 95% CI 1.03–1.14; P < 0.0019), and current use of protease inhibitors (OR 1.64; 95% CI 1.35–2.04; P < 0.0001). Conclusions:Our results show a high prevalence of and considerable progression to osteopenia/osteoporosis in our cohort. Our findings support the importance of applying adequate strategies to prevent bone demineralization and of close monitoring of BMD in HIV-infected patients, specifically in at-risk patients who are taking antiretrovirals that affect bone mineralization.


EBioMedicine | 2016

Gut Microbiota Linked to Sexual Preference and HIV Infection

Marc Noguera-Julian; Muntsa Rocafort; Yolanda Guillén; Javier Rivera; Maria Casadellà; Piotr Nowak; Falk Hildebrand; Georg Zeller; Mariona Parera; Rocío Bellido; Cristina Simarro Rodríguez; Jorge Carrillo; Beatriz Mothe; Josep Coll; Isabel Bravo; Carla Estany; Cristina Herrero; Jorge Saz; Guillem Sirera; Ariadna Torrela; Jordi Navarro; Manel Crespo; Christian Brander; Eugenia Negredo; Julià Blanco; Francisco Guarner; Maria Luz Calle; Peer Bork; Anders Sönnerborg; Bonaventura Clotet

The precise effects of HIV-1 on the gut microbiome are unclear. Initial cross-sectional studies provided contradictory associations between microbial richness and HIV serostatus and suggested shifts from Bacteroides to Prevotella predominance following HIV-1 infection, which have not been found in animal models or in studies matched for HIV-1 transmission groups. In two independent cohorts of HIV-1-infected subjects and HIV-1-negative controls in Barcelona (n = 156) and Stockholm (n = 84), men who have sex with men (MSM) predominantly belonged to the Prevotella-rich enterotype whereas most non-MSM subjects were enriched in Bacteroides, independently of HIV-1 status, and with only a limited contribution of diet effects. Moreover, MSM had a significantly richer and more diverse fecal microbiota than non-MSM individuals. After stratifying for sexual orientation, there was no solid evidence of an HIV-specific dysbiosis. However, HIV-1 infection remained consistently associated with reduced bacterial richness, the lowest bacterial richness being observed in subjects with a virological-immune discordant response to antiretroviral therapy. Our findings indicate that HIV gut microbiome studies must control for HIV risk factors and suggest interventions on gut bacterial richness as possible novel avenues to improve HIV-1-associated immune dysfunction.


Clinical Infectious Diseases | 2009

Improvement of Mitochondrial Toxicity in Patients receiving a Nucleoside Reverse-Transcriptase Inhibitor-Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)

Eugenia Negredo; Òscar Miró; Benjamí Rodríguez-Santiago; Glòria Garrabou; Carla Estany; Àngels Masabeu; Lluis Force; Pilar Barrufet; Josep Cucurull; Pere Domingo; Carlos Alonso-Villaverde; Anna Bonjoch; Constanza Morén; Núria Pérez-Álvarez; Bonaventura Clotet

BACKGROUND Nucleoside reverse-transcriptase inhibitor (NRTI)-related mitochondrial toxicity has been suggested as a key factor in the induction of antiretroviral-related lipoatrophy. This study aimed to evaluate in vivo the effects of NRTI withdrawal on mitochondrial parameters and body fat distribution. METHODS A multicenter, prospective, randomized trial assessed the efficacy and tolerability of switching to lopinavir-ritonavir plus nevirapine (nevirapine group; n = 34), compared with lopinavir-ritonavir plus 2 NRTIs (control group; n = 33) in a group of human immunodeficiency virus-infected adults with virological suppression. A subset of 35 individuals (20 from the nevirapine group and 15 from the control group) were evaluated for changes in the mitochondrial DNA (mtDNA) to nuclear DNA ratio and cytochrome c oxidase (COX) activity after NRTI withdrawal. Dual-energy X-ray absorptiometry (DEXA) scans were used to objectively quantify fat redistribution over time. RESULTS The nevirapine group experienced a progressive increase in mtDNA content (a 40% increase at week 48; P = .039 for comparison between groups) and in the COX activity (26% and 32% at weeks 24 and 48, respectively; P = .01 and P = .09 for comparison between groups, respectively). There were no statistically significant between-group differences in DEXA scans at week 48, although a higher fat increase in extremities was observed in the nevirapine group. No virologic failures occurred in either treatment arm. CONCLUSIONS Switching to a nucleoside-sparing regimen of nevirapine and lopinavir-ritonavir maintained full antiviral efficacy and led to an improvement in mitochondrial parameters, which suggests a reversion of nucleoside-associated mitochondrial toxicity. Although DEXA scans performed during the study only revealed slight changes in fat redistribution, a longer follow-up period may show a positive correlation between reduced mitochondrial toxicity and a clinical improvement of lipodystrophy.


Clinical Infectious Diseases | 2015

The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

José R. Santos; Maria Saumoy; A Curran; Isabel Bravo; Josep M. Llibre; Jordi Navarro; Carla Estany; Daniel Podzamczer; Esteban Ribera; Eugenia Negredo; Bonaventura Clotet; Roger Paredes

BACKGROUND It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated with the lipid-neutral emtricitabine (FTC), has a lipid-lowering effect. METHODS We performed a randomized, crossover, double-blind, placebo-controlled clinical trial on human immunodeficiency virus type 1 (HIV-1)-infected subjects with HIV-1 RNA < 50 copies/mL during ≥6 months on stable darunavir/ritonavir (800/100 mg once daily) or lopinavir/ritonavir (400/100 mg twice daily) monotherapy, fasting total cholesterol (TC) ≥200 mg/dL or low-density lipoprotein cholesterol (LDL-c) ≥130 mg/dL, and no lipid-lowering drugs. In arm 1, TDF/FTC was added for 12 weeks, followed by 12 weeks of placebo (washout) and 12 additional weeks of placebo (placebo period). Subjects in arm 2 added placebo for 12 weeks (placebo period) followed by TDF/FTC for 12 weeks and placebo for 12 additional weeks (washout). The primary endpoint was change in median fasting TC levels. RESULTS Of 46 subjects enrolled, 56% received darunavir/ritonavir and 44% lopinavir/ritonavir. Exposure to TDF/FTC reduced TC from 234 to 205 mg/dL (P < .001), LDL-c from 155 to 128 mg/dL (P < .001), and high-density lipoprotein cholesterol (HDL-c) from 50.3 to 44.5 mg/dL (P < .001). It also decreased the proportion of subjects with fasting TC ≥200 mg/dL from 86.7% to 56.8% (P = .001), and LDL-c ≥130 mg/dL from 87.8% to 43.9% (P < .001). After 12 weeks, TDF/FTC exposure was associated with lower TC and LDL-c levels than placebo (P = .001 and P = .002, respectively). The TC/HDL-c ratio and triglyceride levels did not change with TDF/FTC exposure. CONCLUSIONS Coformulated TDF/FTC has an intrinsic lipid-lowering effect, likely attributable to TDF. CLINICAL TRIALS REGISTRATION NCT01458977.


AIDS | 2007

Therapeutic management of bone demineralization in the Hiv-infected population

Eugenia Negredo; Eva Martínez; Denise Cinquegrana; Carla Estany; Bonaventura Clotet

Bone demineralization is a common metabolic problem in patients infected with HIV [1–7] and the incidence of this problem is actually greater in the HIV-infected population than in the general population [8,9]. The widespread utilization of highly active antiretroviral therapy has notably increased the survival of the HIV-infected population, prolonging the time that patients live with the HIV infection. The increasing age of these individuals, the virus itself, and the presence of other concomitant factors that accelerate the loss of bone mineral density (BMD), are all factors that could explain the high prevalence of osteopenia and osteoporosis in this group, and particularly in the female population as many HIV-infected women reach menopause and experience its typical manifestations, such as osteoporosis.


Hiv Medicine | 2015

Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years

Eugenia Negredo; Anna Bonjoch; Núria Pérez-Álvarez; A Ornelas; Jordi Puig; C Herrero; Carla Estany; L. Del Rio; S. Di Gregorio; P Echeverría; Bonaventura Clotet

Given the need for easily managed treatment of osteoporosis in HIV‐infected patients, we evaluated the efficacy and tolerability of two doses of zoledronate, by comparing three groups of patients: those with annual administration, those with biennial administration (one dose in 2 years) and a control group with no administration of zoledronate.


AIDS Research and Human Retroviruses | 2015

Ten-year safety with polyacrylamide gel used to correct facial lipoatrophy in HIV-infected patients

Eugenia Negredo; Jordi Puig; Arelly Ornelas; Patricia Echeverría; Anna Bonjoch; Carla Estany; Carmen Higueras; Vicente Gonzalez-Mestre; Bonaventura Clotet

Long-term results (>5 years) for synthetic substances used to repair facial lipoatrophy have not been published. We performed a cross-sectional study to evaluate the 10-year safety of polyacrylamide hydrogel (Aquamid) among the 751 patients from our unit who received facial infiltrations at least 10 years ago. Epidemiological and clinical data such as complications and patient satisfaction were collected. We also identified those patients who presented a facial infection at any time after infiltration. A total of 104 patients had received Aquamid at least 10 years ago. Before infiltrations, 24.0%, 41.3%, and 34.7% presented very severe, severe, and moderate facial lipoatrophy, respectively. After a mean (SD) of 10.3 (0.5) years since the infiltrations, 19.2%, 47.7%, and 31.7% of patients reported moderate, mild, and no signs of facial lipoatrophy. The values reported by physicians for the same categories were 1.9%, 10.6%, and 87.5%. Indurations were detected in 6.7% of patients and nodules in 3.8%. Five patients (4.8%) had a local infection. A further 15 patients with a shorter follow-up (less than 10 years) presented local infections (overall incidence considering the 751 patients who received infiltrations of Aquamid, 2.7%); the product had to be withdrawn in three cases. The majority of patients were highly satisfied (74.8%) or satisfied (23.4%) with the cosmetic results; among patients with severe or very severe lipoatrophy at baseline, 31.4% were satisfied and 65.7% were highly satisfied. Infiltrations with polyacrylamide hydrogel (Aquamid) are a safe strategy for the treatment of facial lipoatrophy in the long term. The rate of severe complications was low, and patient satisfaction with the cosmetic results was high. However, facial infections may appear in the long term. Therefore, HIV-infected patients who received synthetic substances should be carefully monitored over time.


Journal of Antimicrobial Chemotherapy | 2016

Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.

Eugenia Negredo; Vicente Estrada; Pere Domingo; Maria del Mar Gutierrez; Gracia Mateo; Jordi Puig; Anna Bonjoch; Arelly Ornelas; Patricia Echeverría; Carla Estany; Jessica Toro; Bonaventura Clotet

Background: Switching from PIs to dolutegravir in virologically suppressed HIV-infected individuals has not been assessed. Objectives: The principal aim was to assess the evolution of bone mineral density (BMD) when switching from a ritonavir-boosted PI to dolutegravir in HIV-infected patients with osteopenia or osteoporosis. The secondary objective was to assess the antiviral efficacy and safety of the switch therapy. Methods: This randomized, multicentre study assessed changes in BMD, bone turnover markers, and antiviral efficacy and safety in 73 virologically suppressed patients with osteopenia/osteoporosis taking a ritonavir-boosted PI plus abacavir/lamivudine who were randomized to switch from PI to dolutegravir (DOLU group, n = 37) or continue with a PI (PI group, n = 36). Clinical Trials: NCT02577042. Results: One and three patients from the DOLU and PI groups, respectively, withdrew prematurely (unrelated to treatment). At 48 weeks, 97.3% versus 91.7%, respectively, maintained viral suppression (snapshot analysis, ITT, M = F). No significant differences were seen between the groups in percentage change from baseline to week 48 in femoral (P = 0.56) and lumbar spine (P = 0.29) BMD, although lumbar spine BMD improved by 1.43% (–1.36; 2.92) in the DOLU group [0.12% (–2.83; 2.89) in the PI group]. Bone marker values did not vary significantly. At week 48, triglycerides were lower (P < 0.001) and HDL cholesterol higher (P = 0.027) in the DOLU group. Conclusions: Dolutegravir + Kivexa® was safe and well-tolerated in virologically suppressed patients receiving a PI-based regimen. The lipid profile was better, albeit without significant changes in BMD, probably because of the short follow-up.


Journal of the International AIDS Society | 2014

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC

José R. Santos; Maria Saumoy; Adrian Curran; Isabel Bravo; Jordi Navarro; Carla Estany; Daniel Podzamczer; Esteban Ribera; Eugenia Negredo; Bonaventura Clotet; Roger Paredes

Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF. [ 1 – 3 ] It is unknown, however, if TDF has an intrinsic lipid‐lowering effect or such findings are due to the addition or removal of other offending agents or other reasons.


Mucosal Immunology | 2018

Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection

Yolanda Guillén; Marc Noguera-Julian; Javier Rivera; Maria Casadellà; Alexander S. Zevin; Muntsa Rocafort; Mariona Parera; Cristina Simarro Rodríguez; Marçal Arumí; Jorge Carrillo; Beatriz Mothe; Carla Estany; Josep Coll; Isabel Bravo; Cristina Herrero; Jorge Saz; Guillem Sirera; Ariadna Torrella; Jordi Navarro; Manuel Crespo; Eugenia Negredo; Christian Brander; Julià Blanco; Maria Luz Calle; Nichole R. Klatt; Bonaventura Clotet; Roger Paredes

Human immunodeficiency virus (HIV)-1 infection causes severe gut and systemic immune damage, but its effects on the gut microbiome remain unclear. Previous shotgun metagenomic studies in HIV-negative subjects linked low-microbial gene counts (LGC) to gut dysbiosis in diseases featuring intestinal inflammation. Using a similar approach in 156 subjects with different HIV-1 phenotypes, we found a strong, independent, dose–effect association between nadir CD4+ T-cell counts and LGC. As in other diseases involving intestinal inflammation, the gut microbiomes of subjects with LGC were enriched in gram-negative Bacteroides, acetogenic bacteria and Proteobacteria, which are able to metabolize reactive oxygen and nitrogen species; and were depleted in oxygen-sensitive methanogenic archaea and sulfate-reducing bacteria. Interestingly, subjects with LGC also showed increased butyrate levels in direct fecal measurements, consistent with enrichment in Roseburia intestinalis despite reductions in other butyrate producers. The microbiomes of subjects with LGC were also enriched in bacterial virulence factors, as well as in genes associated with beta-lactam, lincosamide, tetracycline, and macrolide resistance. Thus, low nadir CD4+ T-cell counts, rather than HIV-1 serostatus per se, predict the presence of gut dysbiosis in HIV-1 infected subjects. Such dysbiosis does not display obvious HIV-specific features; instead, it shares many similarities with other diseases featuring gut inflammation.

Collaboration


Dive into the Carla Estany's collaboration.

Top Co-Authors

Avatar

Bonaventura Clotet

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anna Bonjoch

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Jordi Puig

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Núria Pérez-Álvarez

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Patricia Echeverría

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Jordi Navarro

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge